Sociodemographic disparities in sodium-glucose cotransporter-2 inhibitor use among US kidney transplant recipients: An observational study of real-world pharmacy records

Background: Recent clinical trials demonstrate benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with chronic kidney disease, but data on use in kidney transplant (KTx) recipients are limited. Methods: We examined a novel database linking SRTR registry data for KTx recipients (2000–2021) with outpatient fill records from a large pharmaceutical claims warehouse (2015–2021). Adult (≥18 years) KTx recipients treated with SGLT2i were compared to those who received other noninsulin diabetes medications without SGLT2i. Characteristics associated with SGLT2i use were quantified by multivariable logistic regression (adjusted odds ratio, _95%LCLaOR_95%UCL). Results: Among 18 988 KTx recipients treated with noninsulin diabetes agents in the study period, 2224 filled an SGLT2i. Mean time from KTx to prescription was 6.7 years for SGLT2i versus 4.7 years for non-SGLT2i medications. SGLT2i use was more common in Asian adults (aOR, _1.091.31_1.58) and those aged > 30–59 years (compared with 18–30 years) or with BMI > 35 kg/m² (aOR, _1.191.41_1.67), and trended higher with self-pay status. SGLT2i use was lower among KTx recipients who were women (aOR, _.79.87_.96), Black (aOR, _.77.88_1.00) and other (aOR, _.52.75_1.07) race, publicly insured (aOR, _.82.92_1.03), or with less than college education (aOR, _.78.87_.96), and trended lower in those age 75 years and older. SGLT2i use in KTx patients increased dramatically in 2019–2021 (aOR, _5.015.63_6.33 vs. prior years). Conclusion: SGLT2i use is increasing in KTx recipients but varies with factors including race, education, and insurance. While ongoing study is needed to define risks and benefits of SGLT2i use in KTx patients, attention should also focus on reducing treatment disparities related to sociodemographic traits.